Phase 3 Recruiting Network
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 271 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
- Thomas Hospital — Fairhope, Alabama
+ 115 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…
Sponsor: Pfizer
NCT ID: NCT06989437
Locations: - The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
- The University of Alabama at Birmingham — Birmingham, Alabama
- Central Arkansas Radiation Therapy Institute, dba CARTI — Bryant, Arkansas
+ 69 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Locations: - Investigative Site US058 — Birmingham, Alabama
- Investigative Site US016 — Anchorage, Alaska
- Investigative Site US026 — Chandler, Arizona
+ 65 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Locations: - City of Hope (Adults and Pediatrics) — Duarte, California
- University of California San Diego Moores Cancer Center (Adults only) — La Jolla, California
- Loma Linda University Medical Center (Adults only) — Loma Linda, California
+ 37 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Locations: - Exelixis Clinical Site #43 — Birmingham, Alabama
- Exelixis Clinical Site #36 — Phoenix, Arizona
- Exelixis Clinical Site #42 — Tucson, Arizona
+ 36 more sites in the U.S.
Phase 3 Recruiting Industry
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Sponsor: RenovoRx
NCT ID: NCT03257033
Locations: - VA Loma Linda Healthcare System — Loma Linda, California
- Sutter Cancer Center Sacramento — Sacramento, California
- Rocky Mountain Cancer Centers — Denver, Colorado
+ 33 more sites in the U.S.
Phase 3 Recruiting Industry
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2…
Sponsor: RayzeBio, Inc.
NCT ID: NCT05477576
Locations: - Research Facility — Phoenix, Arizona
- Research Facility — Duarte, California
- Research Facility — Irvine, California
+ 29 more sites in the U.S.
Phase 3 Recruiting Industry
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…
Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Yale University - New Haven Hospital - Yale Cancer Center — New Haven, Connecticut
+ 14 more sites in the U.S.
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Locations: - Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton — Fullerton, California
- Hoag Mem Hosp Presbyterian — Newport Beach, California
- Baptist MD Anderson Cancer Institute — Jacksonville, Florida
+ 11 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07252232
Locations: - University of California, Los Angeles — Los Angeles, California
- University of California, San Francisco — San Francisco, California
- Hartford Healthcare — Hartford, Connecticut
+ 10 more sites in the U.S.
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Locations: - Yale University — New Haven, Connecticut
- Johns Hopkins Hospital — Baltimore, Maryland
- Dana Farber Cancer Center, Harvard University — Boston, Massachusetts
+ 6 more sites in the U.S.